

CURRICULUM VITAE

Flavio Vincenti, M.D.

Professor of Clinical Medicine
University of California, San Francisco
505 Parnassus Avenue, 884M
San Francisco, CA 94143-0780

PERSONAL DATA:

NAME: Flavio Vincenti
SEX: Male
CITIZENSHIP: U.S.A.
BIRTHDATE: December 9, 1944
MARITAL STATUS: Married
LICENSE: C36967
BNDD #: AV 6967256

EDUCATION:

Liceo Italiano, High School
International College of Beirut, Lebanon High School
1967 American University of Beirut, Lebanon, B.S.
1971 American University of Beirut, Lebanon, M.D.

TRAINING:

Internship: American University Medical Center, Beirut, Lebanon
Residency: American University Medical Center, Beirut, Lebanon
Fellowship: Fellow in Nephrology, Emory University School of Medicine,
Atlanta, Georgia, July 1, 1973 - June 30, 1975
Research Fellow, National Kidney Foundation,
July 1, 1974 - June 30, 1975
Fellow in Cardiovascular Research Institute
(Nephrology) University of California, San
Francisco, July 1, 1975 - June 30, 1976

9/16/08

BOARD OF CERTIFICATION:

June 1975 Certified, American Board of Internal Medicine
October 1976 Certified in Nephrology, October, 1976

POSITIONS HELD:

July 1, 2003- Professor of Clinical Medicine and Surgery, UCSF
July 1, 1992- Medical Director of the Kidney-Pancreas Program
July 1, 1985-2003 Clinical Professor of Medicine and Surgery, UCSF
July 1, 1981-1985 Clinical Associate Professor of Medicine and Surgery, UCSF
July 1, 1976-1981 Clinical Assistant Professor of Medicine and Surgery, UCSF

MEDICAL ORGANIZATIONS, SOCIETIES AND COMMITTEES:

American Society of Nephrology
American Society of Transplantation Physicians
International Society of Nephrology
The Transplantation Society
1977-1980 California Kidney Foundation, Scientific Advisory Board
1996-2002 Member of the Recurrent and De Novo Disease Renal
 Allograft Registry
1996-1999 Member of ASTP Programs and Publications Committee
1996-1999 Member of ASTP Kidney-Pancreas Committee
1999-2001 ASN-AST Renal Transplant Training Certification Committee
2002-2005 Chair, Clinical Trials Committee, AST
2003-2006 Elected Counselor-at-Large, American Society of
 Transplantation
2000- Co-Leader of the Solid Organ Subgroup of the Immune
 Tolerance Network
2003-2006 ASN Transplant Advisory Group
2004- Member of Steering Committee, Cooperative Trials in
 Pediatric (Renal) Transplantation (CCTPT) for NIH
2002-2007 Chair of AST Development Committee
2004- Member of AST/ASTS Joint Council
2004-2007 AST Financial Advisory Committee
 Co-Director 2004 AST Winter Symposium
 Co-Director 2004 ASN Post Graduate Course
 Program Chairman for Transplantation, ASN 2005
 Chair AST Winter Meeting, 2006
 Member of the 2006 World Transplant Congress Program
 Committee

Flavio Vincenti -- 3

2007-2008 Member of the 2007 American Transplant Congress Program
Committee
President, American Society of Transplantation

UCSF COMMITTEES

1976-1982 Infection Control Committee
 Ad Hoc Peer Review Committees, UCSF
1990- Director of Annual UCSF Transplant Symposium
1991- AdHoc Search Committee, UCSF
0.
0.

EDITORIAL COMMITTEES

1996-2001 American Journal of Kidney Disease, Editorial Board
1998-2002 *Graft* , Editorial Board
 Peer Review: Journal of American Society of Transplantation,
 New England Journal of Medicine, American Journal of
 Kidney Diseases and Kidney International
2003-2006 Associate Editor, The American Journal of Transplantation
2004- Editorial Board, Transplantation
2005- Associate Editor, CJASN

HONORS-AWARDS

National Kidney Foundation of Northern California "Champion of Hope
Award", May 20, 2000
The American Society of Transplantation 2002, "Novartis Clinical Science
Award"

TEACHING and MENTORING

POSTGRADUATE AND OTHER COURSES

SUMMARY OF TEACHING HOURS (2009-2010): 540 informal teaching
hours/year

TEACHING NARRATIVE

My primary teaching activities consist of teaching and supervising students, residents and fellows while serving as an attending physician on the transplant ward, as well as teaching and supervising the renal fellows in patient care as an attending physician at the outpatient transplant clinic. I also mentored Jesse Qian in being awarded a grant for patients receiving liver-kidney transplants from the American Society of Transplantation. The abstracts of this study were presented at several transplant related meetings. In 2007, I mentored Brian Lee who presented at the American

Society of Transplantation Winter meeting an abstract on steroid withdrawal.

SELECTED LECTURES

1. Medical Grand Rounds, Kaiser Hospital, Walnut Creek, CA, "New Trends in Kidney Transplantation", February 23, 1994.
2. Transplantation Grand Rounds at CPMC, San Francisco, CA, "Focal Glomerulosclerosis: Etiology and treatment", March 4, 1994.
3. Kidney Foundation Symposium of Northern California, "Recurrent Disease", April 22, 1994.
4. Hoffmann-LaRoche, Nutley, New Jersey, "Current Immunotherapy and Outcome Following Kidney Transplantation", July 22, 1994.
5. Renal Grand Rounds, UC, Davis, Davis, CA, "Recurrent Focal Glomerulosclerosis", April 18, 1995.
6. University of Las Vegas, Las Vegas, NV, "New Drug Therapy for Transplantation", May 26, 1995.
7. National Kidney Foundation of Northern California Medical Symposium on Renal Disease, Foster City, CA, "Hepatitis C in Transplantation", September 29, 1995.
8. Kaiser Permanente Medical Center, Renal Grand Rounds, Oakland, CA, "Update on Renal Transplantation", March 12, 1996.
9. Renal Grand Rounds, UC, San Francisco, CA, "FK506-Renal Transplantation", March, 1996.
10. Current and Future Directions of Kidney Transplantation, Silverado Country Club, Napa, CA "New Immunosuppressive Drugs-Advances in Transplantation, May 3, 1996.
11. Nephrology-Dialysis-Transplantation '96, Monterey, CA, " Current and Future Trends in Kidney Transplantation", May 10, 1996.
12. Roche Bioscience, Palo Alto, CA, "Pathophysiology of Chronic Rejection", June 13, 1996.

13. Renal Grand Rounds, UC, San Francisco, CA, "Focal Glomerulosclerosis", September 9, 1996.
14. Renal Grand Rounds, "Recurrent Focal Glomerulosclerosis", Emory University, Atlanta, Georgia, November 6, 1996.
13. Grand Rounds, "Recurrent Focal Glomerulosclerosis", Swedish Hospital, Seattle, Washington.
14. Renal Grand Rounds, UCSF, "Biologic Agents in Transplantation", San Francisco, CA, January 15, 1997.
15. American Society of Transplant Physicians, Tolerance Meeting, Invited Speaker, "Anti T Cell Therapy", Phoenix, Arizona. February 15, 1997.
16. Research Conference, "Recurrent Focal Glomerulosclerosis", Stanford Medical Center, Stanford, CA, March 5, 1997.
17. American Society of Transplant Physicians 16th Annual Meeting, "Targeting T cell Surface Receptors", Chicago, Illinois, May 14, 1997.
18. Canadian Society of Transplantation, "Emerging Induction Therapies", Vancouver, Canada, September 26, 1997.
19. American Society of Nephrology "Emerging Induction Therapies", San Antonio, Texas, November 4, 1997.
20. University of Washington, Renal Grand Rounds, "Recurrent Focal Glomerulosclerosis", Seattle, Washington, Nov. 10, 1997.
21. Seattle Transplant Society, "Emerging Induction Therapies", Seattle, Washington, Nov. 10, 1997.
22. Stanford University, Transplant Grand Rounds "Daclizumab Therapy in Renal Transplantation", Palo Alto, CA, Jan. 22, 1998.
23. University of Minnesota, Transplant Grand Rounds "Emerging Induction Therapy", Minneapolis, Minnesota, Jan. 28, 1998.
24. New Dimensions in Transplantation, Invited Speaker "Zenapax", Florence, Italy, Feb. 18, 1998.
25. American Society of Transplant Physicians, Invited Speaker, Symposium "Targeting the Interleukin 2 Receptor", Chicago, Illinois, May 13, 1998.

26. University of Maryland, Renal Grand Rounds, "Monoclonal Antibodies to the Interleukin 2 Receptor", Baltimore, Maryland, May 20, 1998.
27. International Society of Transplantation, Invited Speaker, "Can Antibody Therapy Spare Other Immunosuppressive Drugs", Montreal, Canada, July 16, 1998.
28. North American Society of Dialysis and Transplantation, "Recurrent Focal Glomerulosclerosis", July 27, 1998, Maui, Hawaii.
29. UCSF Renal Grand Rounds, "Antibody Therapy in Renal Transplantation", August 5, 1998, September 9, 1998, October 21, 1998, San Francisco, CA.
30. NATCO meeting, invited speaker, "Targeting the Interleukin-2 Receptor", August 12, 1998, New York, NY.
31. SEOPF, Invited Speaker, Symposium on Antibody Therapy in Renal Transplantation, September 18, 1998, Palm Beach, Florida.
32. Baylor University, Transplant Grand Rounds, Anti Interleukin 2 Therapy in Renal Transplantation, November 4, 1998, Houston, Texas.
33. Mexican Society of Nephrology and Transplantation, Targeting the Interleukin 2 Receptor, December 4, 1998, Acapulco, Mexico.
34. Nephrology Research Conference at Stanford University, Optimizing Immunosuppression Therapy, February 7, 1999, Palo Alto, California.
35. Transplant Grand Rounds, Stanford University, Optimizing the Use of Anti Interleukin 2 Therapy, February 11, 1999, Palo Alto, California.
36. UCLA Liver Transplant Rounds, Optimizing the Use of Anti-Interleukin 2 Therapy in Kidney and Liver Transplant Recipients, March 16, 1999, Los Angeles, California.
37. Brigham's and Womens Hospital, Renal Grand Rounds, The Role of the Interleukin-2 Receptor Antibodies in Renal Transplantation, April 27, 1999, Boston, Mass.
38. Invited Speaker Sunrise Symposium, Optimizing Long Term Immunosuppression, 18th Annual Meeting of the AST, May 15-19, 1999, Chicago, Illinois.

39. Chair of Anti-CD25 Workshop, 18th Annual Meeting of the AST, May 15-19, 1999, Chicago, Illinois.
40. National Kidney Foundation Symposium, The New Monoclonal Antibodies, April 14, 2000.
41. Invited speaker, Induction Therapy, Mesot, Beirut, June 12, 2000.
42. Symposium on New Monoclonal Antibodies, XVIII International Congress of the Transplantation Society, Rome, Italy, September 1, 2000.
43. Visiting Professor, Vanderbilt University, Recurrent FGS, Nashville, TN, 2000.
44. Invited speaker, American Society of Nephrology's Renal Week 2000, Immunosuppression in Transplantation Revisited: Lesson Learned from the Recent Clinical Trials, Toronto, Ontario, Canada, October 14, 2000.
45. Invited speaker at the 2001 Transplant meeting: What's in the Pipeline, Chicago, IL, May 14, 2001.
46. Invited speaker, 2001 Transplant Odyssey Anti-IL2R Antibodies, Istanbul, Turkey, August 21, 2001.
47. ASN Postgraduate Course, Update on Induction Therapy, October 13, 2001.
48. Invited speaker, Transplant Immunosuppressive 2001: The complete Care of the Transplant Patient, Minneapolis, Minnesota, October 24, 2001.
49. Invited speaker, Transplant Forum, Emerging Anti-IL2R Regimens, Ottawa, Canada, November 2, 2001.
50. Invited speaker, Harvard Medical School Winter Course 2002. (1) The future of induction therapy. (2) Steroids and calcineurin inhibitors free regimens, Naples, Florida, February 17-21, 2002.
51. Invited speaker symposium , American Transplant Congress "What's in the Pipeline?" Washington DC, April 26-May 1, 2002.
52. Visiting professor, University of Alabama, Recurrent focal glomerulosclerosis, Birmingham, Alabama, April 23, 2002.

53. Invited speaker, XIX International Congress of The Transplantation Society, Role of anti-nterleukin-2 receptor antibodies in delayed graft function, Miami, Florida, August 25-30, 2002.
54. Invited speaker, MESOT Drug Minimization in Renal Transplantation, Muscat, Oman, October 22, 2002.
55. Visiting Professor, University of Osaka, Costimulatory Blockade in Renal Transplantation, Osaka, Japan, November 2, 2002.
56. Visiting Professor, University of Texas at Houston, Transplant Grand Rounds: CNI Sparing Regimen, Houston, TX, March 30, 2003.
57. Invited speaker, American Transplant Congress 2003, Drugs in Clinical Trials, Washington DC, May 30-June 4, 2003.
58. Invited speaker, FOCIS meeting, Therapeutic Approaches to Costimulatory Blockade", Paris, France, May 19, 2003.
59. Invited speaker, ATC 2003, Clinical Trial Symposium, Novel Drugs in Clinical Trials, May 30-June 4, 2003.
60. Visiting Professor at Harvard, "Costimulatory Blockade", Boston, MA, September 18, 2003.
61. Invited speaker, Transplant Immunosuppression 2003, "What's in the Pipeline", University of Minnesota, Minneapolis, Minnesota, October 2, 2003.
62. Visiting Professor at Vanderbilt University Renal Grand Rounds "Recurrent Focal Glomerulosclerosis", Nashville, TN, October 30, 2003.
63. Invited Speaker, AST Winter Meeting, "Costimulation Blockade, Phoenix, Arizona, January 19, 2004.
64. Invited Speaker, The 3rd Asia/Oceania Workshop on Immunosuppression, "Immunosuppression Today & Tomorrow", Miyazaki, Japan, April 18, 2004.
65. Visiting Professor, University of Bern, Switzerland, "Proteins and Antiproliferatives", June 17, 2004.

66. Invited Speaker, UCLA 14th Annual Kidney & Pancreas Transplant Symposium, "Patients at High Risk of Recurrence", Los Angeles, CA, September 18, 2004.
67. Invited Speaker, American Society for Histocompatibility & Immunogenetics (ASHI), "Future Challenges in Clinical Trials and Their Endpoints", San Antonio, TX, October 6, 2004.
68. Invited Speaker, American Society of Nephrology symposium on the 50th Anniversary of Renal Transplantation, St. Louis, MI, October 29- November 1, 2004.
69. Invited Speaker, Transplant Asia, "Costimulation Blockade", Singapore, December 2, 2004.
70. Invited Speaker, 3rd International Congress on Immunosuppression, Plenary Session, "New Clinical Trials in Transplantation", San Diego, CA, December 11, 2004.
71. Invited Speaker, ASTS Winter Meeting, "Why we need to innovate in transplant", Miami, FL, January 23, 2005.
72. Harvard Nephrology Winter Course, "Novel immunosuppressive regimens", Naples, FL, February 23, 2005.
73. Renal Grand Rounds, Cedars Sinai, "Rationale Design of Immunosuppression Regimens, Los Angeles, CA, March 29, 2005.
74. Invited Speaker, 32nd Annual Renal Disease and Electrolyte Disorders Course, "New Drugs and Biologics in Renal Transplantation" and "Current Trends in Immunosuppressant Therapies", Aspen, CO, July 26, 2005.
75. Invited Speaker, University of Minnesota, Transplant Immunosuppression 2005: Improving Recipient Outcome, "LEA29Y" and "What's New in the Pipeline?" Minneapolis, MN, September 29 & 30th, 2005.
76. Invited Keynote Speaker, AST Clinical Trials Symposium, "The Importance of Clinical Research in Transplantation: Reviewing Achievements and Current Challenges", Rosemont, IL, September 9, 2005.
77. Invited Speaker, UCSF-Pediatric Nephrology Conference, "Calcineurin Avoidance in Kidney Transplantation", San Francisco, CA, January 17, 2006.

78. Invited Speaker, ASTS Winter Meeting, "Grant Support from Industry, January 19, 2006, Phoenix, Arizona.
79. Invited Speaker, 39th Annual Meeting of the Japanese Transplant Society, "PTDM", January 25, 2006, Kunagana, Japan.
80. Invited Speaker, AST Winter Meeting, "Costimulation Blockade-An Update", February 19, 2006, Cancun, Mexico.
81. Invited Speaker, The Renal Division, Department of Medicine, Brigham and Women's Hospital, "New Immunosuppression Agents", "Recurrent Disease", March 19, 2006, Naples, Florida.
82. UCSF Renal Grand Rounds, "Costimulation Blockade in Transplantation", July 12, 2006, San Francisco, CA.
83. Invited speaker, World Transplant Congress, Postgraduate Course, "Update on Clinical Studies with Costimulation Blockade", July 25, 2006, Boston, MA.
84. UCSF Medical Grand Rounds, "Update on Kidney Transplantation", August 3, 2006, San Francisco, CA.
85. Invited Speaker, XXIV Congreso Nacional, "Recurrent FSGS", "Costimulation Blockade", October 13, 2006, Cancun, Mexico.
86. UCSF Renal Grand Rounds, "New Onset Diabetes After Transplantation", October 18, 2006, San Francisco, CA.
87. Invited Speaker, ASN Renal Week, "Calcineurin Free Regimens in Renal Transplantation", November 18, 2006, San Diego, CA.
88. Invited Speaker, AST Winter Meeting, "Recurrent Disease", February 16, 2007, Phoenix, AZ.
89. Invited Speaker, American Academy of Allergy, Asthma & Immunology Annual Meeting, "Targeting T Cell Co-Stimulation – The CD28 Family of Molecules: Risks/Benefit (CTLA4 vs TGN1412)", February 27, 2007, San Diego, CA.
90. Invited Speaker, Suren Sehgal Memorial, Annual Scientific Meeting, Canadian Society of Transplantation, "New Immunosuppression Regimens to Reduce Toxicities", Fairmont Banff Springs, March 15-18,

- 2007, Banff, AB, Canada.
91. Invited Speaker, American Transplant Congress, "Effect of immunosuppression on T regulatory cells", May 1, 2007, San Francisco, CA.
 92. Invited Speaker, 2007 Joint Conference, "New Drugs in Transplantation", September 17, 2007, Minneapolis, MN.
 93. Visiting Professor, Cornell University, Nephrology Grand Rounds, "Costimulation Blockade", October 16, 2007, New York, NY.
 94. Invited Speaker, Transplant Immunosuppression 2007, "Clinical Trials with Belatacept, A Novel Therapy in Transplantation", October 18, 2007.
 95. Invited Speaker, American Society of Transplantation, "A New Era of Immunosuppression is Here!: Costimulatory Blockade in Clinical Transplant Practice", November 4, 2007, San Francisco, CA.
 96. Invited Speaker, UCSF Outreach Conference, Update in Liver Transplantation 2007 Symposium, May 8, 2008, Napa, CA.
 97. Invited Speaker, American Society of Transplantation, "Belatacept", November 4, 2007, San Francisco, CA.
 98. Invited Speaker, Institute for Cellular Therapeutics Meeting, "Composite Tissue Allotransplantation", January 14, 2008, Los Angeles, CA.
 99. Invited Speaker, Tolerance in Transplantation and Autoimmunity, "Belatacept Therapy in Kidney Transplantation", "T Reg Cells", Keystone, Colorado, January 29, 2008.
 100. Invited Speaker, 8th International Conference on New Trends in Immunosuppression and Immunotherapy, "Costimulation blockade with belatacept in renal transplantation", February 16, 2008, Berlin, Germany.
 101. Invited Speaker, American Society of Transplantation Winter Meeting, "IV Therapy in Transplantation", Palm Springs, CA, March 15, 2008.

PREVIOUS RESEARCH PROJECTS:

- F. Vincenti, Principal Investigator. "The Effect of Cyclosporine in Minimal Change Disease and Focal Glomerulosclerosis", Sandoz Pharmaceuticals Corporation.
- F. Vincenti, Principal Investigator. "The Effect of Tumor Necrosis Factor on Rat Kidneys Cold Stored for 48 Hours", Genentech.
- F. Vincenti, Principal Investigator. "Effect of Trental in OKT3 Treated Patients", Ortho Pharmaceuticals.
- F. Vincenti, Principal Investigator. "An Open Trial of Trental in Ascending Doses for the Treatment of Renal Toxicity Associated with Cyclosporine in Renal, Liver and Heart Transplant Immunosuppression", Hoescht-Roussel Pharmaceuticals Inc.
- F. Vincenti, Principal Investigator. "Pharmacokinetic Study of FK506 Prior and Following Transplantation", Fujisawa Pharmaceuticals.
- F. Vincenti, Principal Investigator. "The Effect of Trental on Radiocontrast Induced Nephropathy", Hoescht-Roussel Pharmaceuticals Inc.
- F. Vincenti, Principal Investigator. "An Open, Multicenter, Parallel Comparative Dose Finding Trial of FK506 in Primary Kidney Transplantation (Phase II)", Fujisawa Pharmaceuticals.
- F. Vincenti, Principal Investigator. "A Multicenter Trial of Trental Versus Placebo for the Prevention of a Nephrotoxicity Associated with Amphotericin B in Fungal Disease", Hoescht-Roussel Pharmaceuticals, Inc.
- F. Vincenti, Principal Investigator: "The Effect of Pentoxifylline versus Placebo for the Prevention of Cytokine Induced First Dose Reactions Following Therapy with ORTHOCLONE OKT3, Ortho Biotech.
- F. Vincenti, Principal Investigator. "Comparative Trial of FK506 Versus Cyclosporine in Patients After Renal Transplantation (Phase III)", Fujisawa Pharmaceuticals.
- F. Vincenti, Principal Investigator. "A Phase I Randomized Trial of Humanized Anti-Tac (R024-7375) for Prevention of Acute Allograft Rejections in Recipients of First Renal Transplants", Hoffman-LaRoche.

- F. Vincenti, Principal Investigator. "A Phase III Randomized Trial of Humanized Anti-Tac for Prevention of Acute Allograft Rejections in Recipients of First Cadaver Renal Transplants", Hoffman-LaRoche.
- F. Vincenti, Principal Investigator. "A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic and Tolerability Study Comparing Humanized Anti-Tac Plus Standard Immunosuppressive Therapy (CellCelt + Neoral + steroids) to Standard Immuno-suppressive Therapy Alone in Patients Receiving Their First Renal Allograft from Non-HLA Identical Donors," Hoffmann-LaRoche.
- F. Vincenti, Principal Investigator. "Pharmacokinetics, Safety, and Tolerability of FK506 and Mycophenolate Mofetil when Used in Combination in Stable Renal Transplant Patients", Fujisawa.
- F. Vincenti, Principal Investigator. "A Randomized, Double-Blind, Dose Ranging Study to Assess the Safety and Efficacy of FK506 and Mycophenolate Mofetil (MMF) when used in Combination in Renal Transplant Recipients". Fujisawa.
- F. Vincenti, Principal Investigator. "Single-Arm Open-Label Phase II Study of the Combination of Dacliximab and Mycophenolate Mofetil with Corticosteroids in the Prevention of Acute Rejection in Recipients of Renal Allografts (Roche #PA15568). Roche Bioscience/Roche Global Development.
- F. Vincenti, Principal Investigator. "#4-101: A Phase I, Open Label, Single Dose, Pharmacokinetic, Pharmacodynamic and Safety Study of Humanized Anti-CD3 Antibody (HuM291) in Patients Receiving Renal Allografts From Living Donors" Protein Design Labs.
- F. Vincenti, Principal Investigator. "CHI-INT-12: A Multicenter, Randomized, Open-Label Trial of Simulect with Rapid Steroid Withdrawal vs. Simulect with Standard Steroid Treatment in Subjects Treated with Neoral and Cellcept for the Prevention of Acute Rejection in Renal Transplantation", Novartis Pharmaceuticals.
- F. Vincenti, Principal Investigator. "A Multicenter, Open-Label, Randomized Study to Determine the Safety of BG9588 (Anti-CD40L Antibody) Therapy Compared to Standard Treatment of Renal Allograft Transplantation", Biogen, Inc.

- F. Vincenti, Principal Investigator. "Duration of Saturation of the Interleukin 2 Receptor on Circulating Lymphocytes in Kidney Transplant Treated with Zenapax". Roche Pharmaceuticals.
- F. Vincenti, Principal Investigator. "A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination with CellCept, Cycloporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation". Roche Laboratories, Inc.
- F. Vincenti, Principal Investigator. "Protocol No. 0468E1-100154: A Comparative, Open Label Study to Evaluate Graft Function in De Novo Renal Allograft Recipients Treated with Either a Reduced Dose or a Standard Dose of Cyclosporine in Combination with Rapamune (Sirolimus) Plus Corticosteroids". Wyeth-Ayerst Pharmaceuticals.
- F. Vincenti, Principal Investigator. "Protocol 3083A1-100-US: A Phase I Randomized, Third Party Unblinded, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of Humanized Anti-B7.1 (h1F1) and Anti B7.2 (h3D1) Antibodies in De Novo Renal Allograft Recipients." Wyeth-Ayerst Pharmaceuticals.
- F. Vincenti, Principal Investigator. "Protocol CEL197: An Open Label Study to Evaluate the Safety and Efficacy of Daclizumab in Combination with Mycophenolate Mofetil, Sirolimus and Steroids in Recipients of Primary Renal Transplants." Roche Pharmaceuticals.
- F. Vincenti, Principal Investigator. Protocol No. PA16290: A Pilot Study of the Pharmacokinetics, Safety and Efficacy of Mycophenolate Mofetil (CellCept®) and Sirolimus (Rapamune®) in Renal Transplantation when used in Conjunction with Daclizumab (Zenapax®) and Corticosteroids. Roche Pharmaceuticals.
- F. Vincenti, Principal Investigator. "Protocol No. HUKT257: A Phase I/II Open Label Multi-center, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics/Pharmacodynamics, and Biological Activity of Subcutaneously Administered Anti-CD 11a (hu1124) in Patients Receiving a Primary Renal Transplant." Xoma (US) LLC.
- F. Vincenti, Principal Investigator. Protocol No. COLO400AUS-05: A Six Month, Multicenter, Randomized, Open-Label Study to Compare the Impact of Neoral® C2 Monitoring on Safety and Efficacy Outcomes in de novo Kidney Transplant Recipients. Novartis Pharmaceutical.

- F. Vincenti, Principal Investigator. "Protocol M67005: The Use of Daclizimab (Zenapax®) and Mycophenolate Mofetil (CellCept®) in Combination with Corticosteroids and Neoral® (Low Dose Versus Withdrawal) to Optimize Renal Function in Recipients of Renal Allografts." Roche Pharmaceuticals.
- F. Vincenti, Principal Investigator. Protocol No. CERL080A2404: An Open-Label Study to Investigate the Clinical Outcomes of Two Immunosuppressive Regimens of Myfortic with Short-Term Steroid Use or Free of Steroids Compared with a Regimen of Myfortic with Standard Steroids in De Novo Kidney Recipients Receiving Simulect® and Neoral®. Novartis Pharmaceuticals.
- F. Vincenti, Principal Investigator. Impact of Improvement of Anemia with Erythropoietin Among the Post-Transplant Population on Quality of Life and Renal Function. (Investigator Initiated Trial) Ortho Biotech.
- F. Vincenti, Principal Investigator. Noninvasive Diagnosis of Transplant Rejection by Flow Cytometric and Microarrays Analyses of Peripheral Blood Lymphocytes. XDX Inc.
- F. Vincenti, Principal Investigator. Protocol No. 0468H1-101164: An Open-Label, Concentration-Controlled, Randomized, 12-Month Study of Prograf® + Rapamune® + Corticosteroids Compared to Cyclosporine Capsules, USP (Modified) + Rapamune® + Corticosteroids in High Risk Renal Allograft Recipients. Wyeth Ayerst Pharmaceuticals.
- F. Vincenti, Principal Investigator: Protocol 0468H1-101497: A randomized open-label study to compare the safety and efficacy of two different sirolimus regimens with a tacrolimus + mycophenolate mofetil regimen in de novo renal allograft recipients (ORION). Wyeth Ayerst Pharmaceuticals. (Funded).

CURRENT RESEARCH PROJECTS:

- F. Vincenti, Principal Investigator. "Protocol No. IM103-100: Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 as Part of a Quadruple Drug Regimen in Renal Transplant Recipients." Bristol-Myer Squibb Pharmaceutical.
- F. Vincenti, Principal Investigator. The Effect of Rituximab on the Development of Anti Donor Antibodies and Resolution of B cell Infiltration in the Renal Allograft of Patients Undergoing Acute Rejection. (Investigator Initiated Trial) Genentech, Inc.

- F. Vincenti, Principal Investigator. #U01 AI055801: Cooperative Clinical Trial in Pediatric Transplantation. "B7 Costimulatory Blockade in Pediatric Transplantation". NIH Subcontract with Children's Hospital, Boston, MA (funded).
- F. Vincenti, Principal Investigator. #U01 AI63623 Novel Therapies of Chronic Allograft Dysfunction, NIH Subcontract with Brigham and Women's Hospital, Boston, MA (funded).
- F. Vincenti, Principal Investigator: Protocol No. IM103027: Belatacept Evaluation of Nephronprotection and Efficacy as First-line Immunosuppression Trial – Extended Criteria Donors, Bristol Myers Squibb.
- F. Vincenti, Principal Investigator. Protocol A3921009: A 6-month, phase 2, multicenter, randomized, open-label, comparative study of 2 dose levels of CP-690,550 administered concomitantly with IL-2 receptor antagonist induction therapy, mycophenolate mofetil and corticosteroids versus a tacrolimus-based immunosuppressive regimen for the prevention of allograft rejection in de novo renal allograft recipients, Pfizer.
- F. Vincenti, Principal Investigator. Protocol No. IM103008: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial, Bristol-Myers Squibb (Funded).
- F. Vincenti, Principal Investigator. Protocol ITN023ST: The safety and efficacy of belatacept, daclizumab, and sirolimus in recipients of non-HLA-identical living-donor renal transplants. Immune Monitoring Network NIH, Investigator initiated trial. (Funded).
- F. Vincenti, Principal Investigator. Protocol AEB072A2203: 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to *Myfortic*® after 3 months), vs. *Myfortic*® plus tacrolimus in *de novo* renal transplant recipients. Novartis Pharmaceuticals. (Funded).
- F. Vincenti, Principal Investigator. Protocol CAEB071A2207: A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus in combination with *myfortic*®, *Simulect*® and corticosteroids in de novo adult renal transplant recipients. Novartis Pharmaceuticals. (Funded).

- F. Vincenti, Principal Investigator. Protocol No. NT18435: A randomized, double-blind, placebo controlled multi-center study of the efficacy and safety of up to 100 days of valganciclovir vs. up to 200 days of valganciclovir for prevention of cytomegalovirus disease in high-risk kidney allograft recipients. Roche Pharmaceuticals. (Funded).
- F. Vincenti, Principal Investigator. Protocol IM103-010: Belatacept Conversion Trial in Renal Transplantation. Bristol Myers Squibb. (Funded).
- F. Vincenti, Principal Investigator. Protocol No. IM103034: A randomized, open-label, multicenter, parallel-group study of belatacept-based corticosteroid-free regimens in renal transplant. Bristol Myers Squibb. (Funded).
- F. Vincenti, Principal Investigator. Protocol No. A3921030: A phase 2 randomized, multicenter, active comparator-controlled trial to evaluate the safety and efficacy of coadministration of CP-690,550 and mycophenolate mofetil/mycophenolate sodium in de novo kidney allograft recipients. Pfizer. (Funded).

PUBLICATIONS:

1. Vincenti F, Birbari A, Rizk G: Renal vein renin in hypertension diagnostic and therapeutic implications. *Lebanese Med J* 1:26, 1973.
2. Vincenti F, Hajjar E, Salti IS: Tumorous hyperparathyroidism in hypophosphatemic vitamin D-resistant rickets. *Lebanese Med J* 26:583, 1973.
3. Kiblawi S, Vincenti F, Chorra MC, Balikian J: The syndrome of pulmonary infiltrate with eosinophilia: Report of a documented case and review of literature. *Lebanese Med J* 26:125, 1973.
4. Vincenti F, Ibawaii M, Audi M, Birbari A: Changing hemodynamic in a patient with labile hypertension. *Lebanese Med J* 26:655, 1973.
5. Hajjar ET, Vincenti F, Salti I: Gluten-induced enteropathy-osteomalacia as its principal manifestation. *Arch Int Med* 134:565, 1974.
6. Amend WJC, Vincenti F, Covey C, Epstein W, Feduska N, Salvatierra O: Renal transplantation in systemic lupus erythematosus. *Proceedings of the Kidney Foundation Clinical Dialysis and Transplant Forum Systemic Lupus Erythematosus. Proceedings of the Kidney Foundation Clinical Dialysis and Transplant Forum VII:18, 1977.*

7. Vincenti F, Heymsfield S: Reversible malignant hypertension with azotemia secondary to urethral stricture. *Arch Int Med* 136:370, 1978.
8. Vincenti F, Goldberg LI: Combined use of dopamine and postaglandin A in patients with acute renal failure and hepatorenal syndrome. *Postaglandins* 15:463, 1978.
9. Vincenti F, Denes AE, Berquist KR, Duca RM, Cochrum KC, Feduska NJ, Salvatierra O: The role of anti-HBs in renal transplantation. *Dialysis and Transplantation* 7:233, 1978.
10. Feduska NJ, Belzer FO, Stieper KW, Duca RM, Mitchell JW, Vincenti F, Cochrum KC, Salvatierra O: A ten year experience with cadaver kidney preservation using cryoprecipitated plasma. *Am J Surg* 135:356, 1978.
11. Cochrum KC, Hanes DM, Salvatierra O, Feduska NJ, Vincenti F, Van Spreybroeck J: Leukocyte migration inhibitory factor (LIF) as an indicator of presensitization and allograft survival. *Transpl Proc* 10:455, 1978.
12. Feduska NJ, Belzer FO, Stieper KW, Duca RM, Mitchell JW, Vincenti F, Cochrum KC, Salvatierra O: A specialized multidisciplinary approach to cadaver renal transplantation. *Materia Medica Polona* 19:77, 1978.
13. Vincenti F, Duca RM, Amend WJC, Perkind HA, Cochrum KC, Feduska NJ, Salvatierra O: Immunologic factors determining survival of cadaver-kidney transplants. *N Engl J Med* 299:793, 1978.
14. Vincenti F, Amend WJC, Maglio M, Axel L, Cochrum KC, Feduska NJ, Salvatierra O: The effect of hypothermic pulsatile perfusion of glomerular surface structures studied by scanning electron microscopy. *ASAIO* 24:257, 1978.
15. Feduska NJ, Belzer FO, Stieper KW, Duca RM, Mitchell JW, Vincenti F, Cochrum KC, Salvatierra O: Retrieval of cadaver kidneys within a large geographical region with transplantation in a single hospital. *Acta Medic Polona* 19:77-87, 1978.
16. Feduska NJ, Amend WJC, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O: Cadaver kidney transplantation provided from one center within a large geographical region. *Transactions of the American Society for Artificial Internal Organs* 24:270, 1978.
17. Cochrum KC, Hanes D, Van Spreybroeck J, Perkins H, Ferrone S, Indereri F, Amend WJC, Vincenti F, Feduska NJ, Salvatierra O: HLA-D antigen

- disparity and HLA DRW antibodies in intrafamilial renal allograft survival. *Transpl Proc* 11:404, 1979.
18. Van Spreybroeck J, Feduska NJ, Amend WJC, Vincenti F, Cochrum KC, Salvatierra O: The influence of donor age on graft survival. *Am J Surg* 137:374, 1979.
 19. Feduska NJ, Vincenti F, Amend WJC, Duca RM, Cochrum KC, Salvatierra O: Do blood transfusions enhance the possibility of a compatible blood transplant? *Transplantation* 27:35, 1979.
 20. Salvatierra O, Feduska NJ, Vincenti F, Duca RM, Potter D, Cochrum KC, Amend WJC: Analysis of costs and outcomes of renal transplantation at one center: Its implications. *JAMA* 241:1469, 1979.
 21. Spring DB, Salvatierra O, Palubniskas AJ, Amend WJC, Vincenti F, Feduska NJ: Results and significance of arteriography in related potential kidney donors. *Radiology* 133:45, 1979.
 22. Feduska NJ, Collins G, Amend WJC, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O: Comparative study of albumin solution and cryoprecipitated plasma for renal preservation: A preliminary report. *Transpl Proc* 11:472, 1979.
 23. Vincenti F, Amend WJC, Feduska NJ, Duca RM, Salvatierra O: Post-transplantation cytotoxic antibodies do not segregate kidney transplant recipients into responder/non-responder groups. *Proceedings of the European Dialysis and Transplant Association*, 16:419, 1979.
 24. Cochrum K, Hanes D, Potter D, Vincenti F, Amend WJC, Feduska NJ, Perkins H, Salvatierra O: Donor specific blood transfusions in HLA-D disparate 1-haplotype related allografts. *Transpl Proc* 11:1903, 1979.
 25. Wolfe JL, Perkins H, Vincenti F: The transplanted kidney as a source of hepatitis B infection. *Ann Int Med* 91:412, 1979.
 26. Vincenti F, Amend WJC, Feduska NJ, Duca RM, Salvatierra O: Improved outcome following renal transplantation with reduction in immunosuppression therapy for rejection episodes. *Am J Med* 69:107-112, 1980.
 27. Pearson JC, Amend WJC, Vincenti F, Feduska NJ, Salvatierra O: Post-transplantation pyelonephritis: Factors producing low patient and transplant morbidity. *J Urol* 123:153-156, 1980.

28. Salvatierra O, Vincent F, Amend WJC, Potter D, Cochrum K, Hanes D, Opelz G, Iwaki Y, Terasaki P, Stoney RJ, Feduska NJ: Deliberate donor-specific blood transfusions prior to having elated renal transplantation. A new approach. *Ann Surg* 192:113-120, 1980.
29. Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O, Amend WJC: Prednisolone disposition in cushingoid and non-cushingoid kidney transplant patients. *J Clin Endo and Metab* 31(3):561-565, 1980.
30. Vincenti F, Amend WJC, Feduska NJ, Abele J, Salvatierra O: The role of hypertension in hemodialysis-associated atherosclerosis. *Am J Med* 68:363-369, 1980.
31. Hopper SA, Feduska NJ, Vincenti F, Amend WJC, Potter D, Stoney R, Duca RM, Feduska NJ: Organization of successful donor-specific transfusion protocol in related recipients with high MLC. *Proceedings of CDTF*, 1980.
32. Salvatierra O, Amend WJC, Vincenti F, Potter D, Cochrum K, Hanes D, Opelz G, Iwaki Y, Terasaki P, Duca RM, Hanes D, Hopper S, Feduska NJ: Pre-transplant with donor-specific blood transfusions in related recipients with high MLC. *Transpl Proc* 13:142, 1981.
33. Feduska NJ, Amend WJC, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O: Graft survival with high levels of cytotoxic antibodies. *Transplant Proc* 13:73, 1981.
34. Cochrum K, Hanes D, Potter D, Perkins H, Amend WJC, Vincenti F, Iwaki Y, Opelz G, Tersaki P, Feduska NJ, Salvatierra O: Improved graft survival with donor specific transfusion pre-treatment. *Transpl Proc* 13:190, 1981.
35. Cogan M, Sargent J, Yarborough S, Vincenti F, Amend WJC: Prevention of prednisone-induced negative nitrogen balance. *Ann Int Med* 95:158-161, 1981.
36. Amend WJC, Vincenti F, Feduska NJ, Jackson J, Johnson W, Tilney W, Garovoy M, Salvatierra O, Burwell E: Recurrent systemic lupus erythematosus involving renal allografts. *Ann Int Med* 94:444-448, 1981.
38. Hopper SA, Feduska NJ, Vincenti F, Amend WJC, Salvatierra O: Organization of successful donor-specific transfusion protocol in related recipients with high MLC. *Proceedings of CDTF*, 1980.

39. Salvatierra O, Iwaki Y, Vincenti F, Amend WJC, Potter D, Stoney R, Duca RM, Feduska NJ: 1500 renal transplants at one center: The evolution of a strategy for optimum success. *Am J Surg* 142:14-20, 1981.
40. Salvatierra O, Iwaki Y, Vincenti F, Amend WJC, Potter D, Opelz G, Terasaki P, Duca RM, Hopper S, Feduska NJ: Incidence, characteristics and outcome of recipients sensitized after donor-specific blood transfusions. *Transplantation* 32:528-531, 1981.
41. Smith DE, Gambertoglio J, Vincenti F, Benet LZ: Furosemide kinetics and dynamics after kidney transplant. *Clin Pharmacol Ther* 30:105-113, 1981.
42. Feduska NJ, Amend WJC, Vincenti F, Perkins HA, Opelz G, Terasaki PI, Iwaki I, Duca R, Dodge D, Salvatierra O: Graft survival with high levels of cytotoxic antibodies. *Transpl Proc* 13:73-80, 1981.
43. Vincenti F, Hattner R, Amend WJC, Feduska NJ, Duca RM, Salvatierra O: Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. *JAMA* 245:930-933, 1981.
44. Feduska NJ, Vincenti F, Amend W, Iwaki Y, Opelz G, Terasaki R, Duca R, Hopper S, Salvatierra O: An alternative to cadaver kidney transplants for patients with insulin-dependent diabetes mellitus. *Transplantation* 32:517-521, 1981.
45. Salvatierra O, Amend WJC, Vincenti F, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Hanes D, Cochrum KC, Hopper S, Feduska NJ: Pretreatment with donor-specific blood transfusions in related recipients with high MLC. *Transpl Proc* 13:142-149, 1981.
46. O'Connor DT, Barg AP, Amend WJC, Vincenti F: Urinary Kallikrein excretion after renal transplantation. Relationship to hypertension graft source and renal function. *Am J Med* 73:475-481, 1981.
47. Vincenti F, Amend WJC, Feduska NJ, Salvatierra O: Septic arthritis following renal transplantation. *Nephron* 30:253-256, 1982.
48. Amend WJC, Vincenti F, Duca RM, Feduska NJ, Cochrum K, Potter D, Salvatierra O: Prognostic features of early renal transplant rejections. *Am J Kid Dis* 1:281-287, 1982.
49. Gambertoglio JG, Frey FJ, Holford NHG, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O, Amend WJC: Prednisone and prednisolone bioavailability in renal transplant patients. *Kidney Int* 21:621-626, 1982.

50. Salvatierra O, Iwaki Y, Vincenti F, Amend WJC, Terasaki P, Garovoy M, Duca RM, Hopper S, Feduska NJ: Update of the University of California at San Francisco experience with donor-specific blood transfusions. *Transpl Proc* 14:363, 1982.
51. Feduska NJ, Amend WJC, Vincenti F, Duca R, Salvatierra O: Blood transfusions before and on the day of transplantation: Effects on cadaver graft survival. *Transpl Proc* 14:302, 1982.
52. Berger B, Vincenti F, Biava C, Amend WJC, Feduska NJ, Salvatierra O: De novo and recurrent membranous glomerulopathy following kidney transplantation. *Transplantation* 35:315, 1983.
53. Salvatierra O, Amend WJC, Vincenti F, Garovoy M, Potter D, Hopper S, Feduska NJ: Donor-specific blood transfusions (DST). *Dialysis and Transplantation* 12:99, 1983.
54. Salvatierra O, Vincenti F, Amend WJC, Feduska NJ: Four year experience with donor-specific blood transfusions. *Transpl Proc* 15:924, 1983.
55. Salvatierra O, Vincenti F, Amend WJC, Potter D, Feduska NJ: The role of blood transfusions in renal transplantation. *Urol Clin No Amer* 10:243, 1983.
56. Salvatierra O, Vincenti F, Amend WJC, Garovoy M, Feduska NJ: The enhancement of graft survival with pretransplant blood transfusions. *Heart Transpl* 2:181, 1983.
57. Salvatierra O, Amend WJC, Vincenti F, Potter D, Garovoy M, Slemmer T, Feduska NJ: Experience with 1800 renal transplants at the University of California, San Francisco. *Proceedings of the IXth International Congress of Societe Internationale d'Urologie*, 1983.
58. Vincenti F, Arnaud S, Recker R, Genant H, Amend WJC, Feduska NJ, Salvatierra O: The parathyroid and bone response of the diabetic patient to uremia. *Kidney Int* 25:677, 1984.
59. Vincenti F, Amend WJC, Feduska NJ, Birnbaum J, Kaysen G, Duca RM, Salvatierra O: Long term renal function in kidney donors: Sustained compensatory hyperfiltration with no adverse effects. *Transplantation* 36:626-629, 1984.

60. Feduska NJ, Amend WJC, Vincenti F, Duca RM, Hopper S, Salvatierra O: Perfusion preservation of cadaver kidneys: A fifteen year experience. *Transpl Proc* 16:307, 1984.
61. Feduska NJ, Amend WJC, Vincenti F, Melzer JS, Duca R, Garovoy M, Salvatierra O: Peptic ulcer disease in kidney transplant recipients. *Am J Surg* 148:51, 1984.
62. Feduska NJ, Melzer J, Amend WJC, Vincenti F, Duca R, Garovoy M, Hopper S, Salvatierra O: Dramatic improvement in the success rate for renal transfusions. *Transplantation* 38:704-708, 1984.
63. Feduska NJ, Melzer J, Amend WJC, Vincenti F, Duca RM, Garovoy M, Hopper S, Salvatierra O: Donor-specific transfusions prior to renal transplantation in diabetic recipients. *Transpl Proc* 1:1066-1068, 1985.
64. Garovoy MR, Colombe BW, Melzer J, Feduska NJ, Shields C, Cross D, Amend WJC, Vincenti F, Duca R, Salvatierra O: Flow cytometry cross matching for DST recipients in cadaver transplantation. *Transpl Proc* 17:693-695, 1985.
65. Feduska NJ, Melzer J, Amend W, Vincenti F, Duca R, Garovoy M, Hopper S, Salvatierra O: Donor-specific transfusions in diabetic and non-diabetic recipients of related transplants. *Transplantation and Clinical Immunology; Proceedings of the 16th International Course on Transplantation, Lyon, France XVI:83-88*. Touraine JL, et al (Ed). Elsevier Science Publishers BV, Amsterdam, The Netherlands, 1985.
66. Salvatierra O, Melzer J, Garovoy M, Vincenti F, Amend WJC, Hopper S, Feduska NJ: 7-year experience with donor-specific blood transfusions (DSTs): Results and considerations for maximum efficacy. *Transplantation* 40:654-659, 1985.
67. Feduska NJ, Terrier F, Vincenti F, Biava CG, Amend WJC, Melzer J, Salvatierra O, Duca R, Hricak-Hargulis H: Evaluation of acute rejection and cyclosporine nephrotoxicity in renal transplant recipients by magnetic resonance imaging. *Transpl Proc* 17:2597-2599, 1985.
68. Sabile C, Bernhardt JP, Colombe BW, Huebner K, Wood D, Lim V, Amend WJC, Vincenti F, Melzer J, Feduska NJ, Salvatierra O, Garovoy MR: Study of presensitization by flow cytometry in cadaveric kidney recipients. *Proc of the European Dial & Transpl* 22:622, 1985.

69. Stabile C, Bernhardt JP, Colombe BW, Huebner K, Wood D, Lim V, Amend WJC, Vincenti F, Melzer J, Feduska N, Salvatierra O, Garovoy MR: Study of pre-sensitization by flow cytometry in cadaver kidney recipients. Proc of the XXII Congress of the European Dialysis and Transplant Association 22:622-626, 1985.
70. Bachman U, Biava C, Amend WJC, Feduska NJ, Melzer JS, Salvatierra O, Vincenti F: The clinical course of IgA-nephropathy Henoch-Schonlein's purpura following renal transplantation. Transplantation 42:511, 1986.
71. Feduska NJ, Amend WJC, Vincenti F, Tomlanovich S, Melzer J, Salvatierra O: Analysis of some factors which might affect the outcome for cadaveric kidney transplants in cyclosporine-treated patients. Transpl Proc 18:519-52, 1986.
72. Feduska NJ, Amend WJC, Vincenti F, Tomlanovich S, Melzer J, Salvatierra O: Clinical Management of immunosuppressive therapy for cyclosporine-treated patients. Transpl Proc 18:136-140, 1986.
73. Hoddick W, Filly RA, Bachman U, Callen PW, Vincenti F, Hricak H, Mahony B, Amend WJC: Renal allograft rejection: US evaluation. Radiology 161:469-473, 1986.
74. Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJC, Garovoy M, Salvatierra O: Has cyclosporine really relegated pre-transplant blood transfusions to therapeutic obsolescence? Transpl Proc 19:1971-1973, 1987.
75. Feduska NJ, Perkins HA, Melzer J, Amend WJC, Vincenti F, Tomlanovich S, Garovoy M, Salvatierra O: Observations relating to the incidence of acquired immune deficiency syndrome and other possibly associated conditions in a large population of renal transplant recipients. Transpl Proc 19:2161-2166, 1987.
76. Linkowski GD, Warvariv V, Filly RA, Vincenti F: An assessment of the role of ultrasonography in diagnosis of acute renal rejection and cyclosporine (CyA) nephrotoxicity. Am J Roentgenology 148:291-295, 1987.
77. Melzer J, Husing RM, Feduska NJ, Tomlanovich S, Vincenti F, Amend WJC, Garovoy M, Salvatierra O: The beneficial effect of pretransplant blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation 3:61-65, 1987.

78. Hricak H, Terrier F, Marotti M, Engelstad BL, Filly RA, Vincenti F, Duca RM, Bretan PN, Higgins CB, Feduska NJ: Post transplant renal rejection: Comparison and quantitative scintigraphy, US and MR imaging. *Radiology* 162:685-688, 1987.
79. Salvatierra O, Melzer J, Vincenti F, Amend WJC, Tomlanovich S, Potter D, Husing R, Garovoy M, Feduska NJ: Current controversies: Donor-specific blood transfusions (DST) vs. cyclosporine—the DST story. *Transplant Proc* 19:160-166, 1987.
80. Feduska NJ, Melzer JS, Amend WJC, Tomlanovich SJ, Vincenti F, Garovoy M, Husing RM, Salvatierra O: Cyclosporine provides better success rates for both higher and lower-risk cadaver kidney transplant recipients. *Transpl Proc* 20(Suppl 3):102-109, 1988.
81. Tomlanovich SJ, Vincenti F, Amend WJC, Biava C, Melzer J, Feduska NJ, Salvatierra O: Is cyclosporine effective in preventing recurrence of immune-mediated glomerular disease following renal transplantation. *Transpl Proc* 20(Suppl 4):285-288, 1988.
82. Melzer J, Husing R, Feduska NJ, Tomlanovich S, Vincenti F, Amend WJC, Garovoy MR, Lou C, Salvatierra O: How to improve results for second renal allografts. *Transplantation Proceedings* 20 (Suppl 3):176-179, 1988.
83. Tomlanovich SJ, Sabatte-Caspillo J, Melzer JM, Amend WJC, Vincenti F, Feduska NJ, Salvatierra O: The incidence and impact of herpes simplex virus infections in the first month following renal transplantation. *Transplantation Proceedings* 21:2091, 1989.
84. Vincenti F, Biava C, Tomlanovich S, Amend WJC, Garovoy M, Melzer J, Feduska N, Salvatierra O: Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. *Transplantation* 47:595-598, 1989.
85. Lockard-Marduel A, Gumbert M, Tomlanovich S, Amend WJC, Vincenti F, Schralla P, Melzer J, Feduska NJ, Salvatierra O, Garovoy MR: Immunologic alterations induced by donor specific transfusions (DST). *Transplantation Proceedings* 21:1171-1172, 1989.
86. Melzer J, Husing R, Lou C, Feduska NJ, Tomlanovich S, Vincenti F, Amend WJC, Garovoy MR, Salvatierra O: Successful management of the highly sensitized renal allograft recipient. *Transplantation Proceedings* 21:751-753, 1989.

87. Amend W, Soskin T, Vincenti F, Tomlanovich S, Garovoy M, Melzer J, Feduska N, Husing B, Salvatierra O: Long-term experience in primary cadaver renal transplants using cyclosporine. *Clin Transplantation* 4:341-346, 1990.
88. Salvatierra O, McVicar J, Melzer J, Amend W, Vincenti F, Tomlanovich S, Husing R, Rabkin J, Garovoy M. Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol. *Transpl Proc* 23:1024-26, 1991.
89. Stempel C, Lake J, Ferrell L, Tomlanovich SJ, Melzer J, Amend WJC, Salvatierra O, Vincenti F: Effect of cyclosporine on the clinical course of HBsAG-positive renal transplant patients. *Transpl Proc* 23:1251-1252, 1991.
90. Vincenti F, Weber P, Kuo G, Forsell J, Hunt S, Melzer J, Salvatierra O, Stempel C: Hepatitis C virus in cadaver organ donors: prevalence and risk of transmission to transplant recipients. *Transpl Proc* 23:2651-2652, 1991.
91. Krams SM, Falco DA, Villanueva JC, Rabkin J, Tomlanovich SJ, Vincenti F, Amend WJC, Melzer J, Garovoy MR, Roberts JP, Ascher NL, Martinez OM. Cytokine and T cell receptor (TcR). *Transplantation* 53:151-156, 1992.
92. Artero M, Biava C, Amend WJC, Tomlanovich SJ, Vincenti F: Recurrent focal glomerulosclerosis: natural history and response to therapy. *Amer J Med* 92:375-383, 1992.
93. Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C: Prevalence in end-stage renal failure patients and clinical course after kidney transplant. *Transplantation* 55:273-276, 1993.
94. Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel C. Lack of transmission of hepatitis C from cadaver kidney donors to transplant recipients. *Transplantation* 55:674-75, 1993.
95. Vincenti F, Vasconcelos M, Birnbaum J, Tomlanovich SJ, Amend WJC, Melzer JS, Snyder JP. Pentoxifylline reduces the first dose reactions following OKT3. *Transplantation Proceedings* 25(Suppl 1):57-59, 1993.
96. Artero ML, Sharma R, Savin VJ, Vincenti F: Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with

- recurrent focal glomerulosclerosis. *American Journal of Kidney Diseases* 23:574-581, 1994.
97. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK506 multicenter concentration control study: one-year follow-up. *Transplantation Proceedings* 27:809-11, 1995.
 98. Savin VJ, Sharma R, Sharma M, McCarthy E, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Wood E, Chonko AM, Fine R, Trachtman H, Artero M, Vincenti F. Association of circulating factor with recurrence of focal segmental glomerular sclerosis in renal allografts and partial characterization of this factor. *New Eng J Med* 334:878-883, 1996.
 99. Orloff SL, Stempel CA, Wright TL, Tomlanovich ST, Amend WJC, Stock PG, Bretan P, Melzer JS, Vincenti F. Long term outcome in kidney transplant patients with hepatitis C (HCV) infection. *Clinical Transplantation* 9:119-124, 1995.
 100. Sorof JM, Vartanian RK, Olson JL, Tomlanovich SJ, Vincenti FG, Amend WJC: Histopathological concordance of paired renal allograft biopsy cores: Effect on the diagnosis and management of acute rejection. *Transplantation* 60:1215, 1995.
 101. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F, et al. The risk of transmission of hepatitis B from HbsAg (-), HBIGM (-) organ donors. *Transplantation* 1995; 59:230-4.
 102. Vincenti F, Danovitch G, Neylan J, Steiner RW, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine induced first dose reaction following OKT3: A randomized double blind placebo controlled study. *Transplantation*, 61:573-577, 1996.
 103. Lam PWY, Wachs ME, Somberg KA, Vincenti F, Lake, JR, Ferrell LD. Fibrosing cholestatic hepatitis in renal transplant recipients. *Transplantation* 61:37881, 1996.
 104. Vincenti F, Laskow DA, Matas A, Mendez R, Neylan JF. One-year follow-up from an open-label trial of FK506 in primary kidney transplantation. *Transplantation*, 61:1576-1581, 1996.
 105. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas, A. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation. *Transplantation* 62:900-905, 1996.

106. Stock PG, Lantz M, Light S, Vincenti F: In-vivo (Phase I) trial and in-vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. *Transplantation Proceedings*, 28:915-916, 1996.
107. Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, Vincenti F, Burrows L, Schwartz B, Danovitch GM, Wilkinson AH, Shaffer D, Simpson MA, Freeman RB, Rohrer RJ, Mendez R, Aswad S, Munn SR, Wiesner RH, Delmonico FL, Neylan J, Whelchel J for the Tacrolimus Kidney Transplantation Rescue Study Group. A Multicenter Trial of FK506 (Tacrolimus) Therapy in Refractory Acute Renal Allograft Rejection. *Transplantation* 62:594-599, 1996.
108. Vincenti F, Lantz M, Birnbaum J, Garovoy M, Su S, Amend W, Tomlanovich S, Mould D, Litchman M, Light S: A phase I trial of humanized anti-Tac with standard immunosuppression for the prevention of rejection in renal transplant recipients. *Transplantation* 1997;63:33-38.
109. Bretan PN, Freise C, Goldstein RB, Osorio RW, Tomlanovich S, Amend W, Mathur V, Vincenti F. Immunologic and patient selection strategies for successful utilization of less than 15 kg pediatric donor kidneys-long term experiences with 40 transplants. *Transplantation*, 1997;63(2):233-7.
110. Bretan PN, Freise C, Goldstein R, Osorio R, Tomlanovich S, Amend W, Mathur V, Vincenti F. Selection strategies for successful utilization of less than 15 kg pediatric donor kidneys. *Transplantation Proceedings*, 1997 (Dec, 29(8):3274-5.
111. Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS and the FK506 Kidney Transplant Study Group. FK506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. *Transplantation Proceedings* 29:304-5, 1997.
112. Pirsch JD, Miller J, Deierhoi M, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. *Transplantation* 63:977-83, 1997.
113. Bumgardner GL, Amend WC, Ascher NL, Vincenti F: Single-center long-term results of renal transplantation for IgA nephropathy. *Transplantation* 65:1053-1060, 1998.

114. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin 2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. *New England Journal of Medicine*, 1998 Jan 15, 338(3):161-5.
115. Solez K, Vincenti F, Filo R, and the U.S. FK506 Kidney Transplant Study Group. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. *Transplantation* 1998; 66:1736-1740.
116. Vincenti F, Nashan B, Light S, for the Double Therapy and the Triple Therapy Study Groups: Daclizumab: Outcome of phase III trials and mechanism of action. *Transplantation Proceedings* 1998;30:2155-2158.
117. Vincenti F, Grinyo J, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H and Johnson R. Can antibody prophylaxis allow sparing of other immunosuppressives? *Transplantation Proceedings* 1999;31:1246-1248.
118. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza AM, Vincenti F and George V. Recurrent and de novo glomerular disease after renal transplantation: A report from renal allograft disease registry. *Transplantation*, 1999; 68:635-641.
119. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza Am, Vincenti F, George V: Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry. *Transplantation Proceedings* 1999; 31: 223-4.
120. Vincenti F. Potential of daclizumab in solid organ transplantation. *BioDrugs* 1999; 11:333-41.
121. Korsun A, Vincenti F, Ruck D, Whitelaw N, Ladoulis C, Whitelaw G: The role of daclizumab in balancing resources for inpatient and outpatient transplant services. *Progress in Transplantation* 2000; 10:21-24.
122. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE: Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. In Press, *Transplantation*, 2000.

123. Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, Kruelle M, Fass, N, Facklam D, Mekki Q: Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. *Journal of Clinical Pharmacology* 2000; 40:527-532.
124. Ekberg H, Backman L, Tufveson G, Tyden G, Nashan B, Vincenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. *Transplant International* 2000;13:151-9.
125. Chang GL, Mahanty HD, Vincenti F, Friese CE, Roberts JP, Ascher NL, Stock PG, Hirose R. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. *Clinical Transplantation* 2000; 14:550-4.
126. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia, M, Light SE. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. *Transplantation* 2000; 70:1707-12.
127. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan J, Roza A, Somberg K. Rapid steroid withdrawal vs. standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. *Transplantation Proceedings*, 2001; 33:1011-12.
128. Vincenti F. The role of newer monoclonal antibodies in renal transplantation. *Transplantation Proceedings* 2001; 33:1000-01.
129. Vincenti F and the Tacrolimus Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation: Five-year survival results of the US multicenter, randomized, comparative trial. *Transplantation Proceedings*, 2001; 33 (1-2):1019-20.
130. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. *Transplantation* 2001 71(9):1282-7.
131. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal

- transplantation. Phase III Daclizumab Study Group, *Transplantation* 2001 72(5):839-45.
132. Bumgardner GL, Ramos E, Lin A, Vincenti F. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Daclizumab Triple Therapy and Double Therapy Groups, *Transplantation* 2001 72(4):642-7.
 133. Vincenti F. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen. *Transplantation Proceedings* 2001 33 (4 Suppl):11S-18S.
 134. Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Current use and emerging regimens. *Transplantation Proceedings* 2001; 33:3169-71.
 135. Vincenti F, Jensik SC, File RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. *Transplantation* 2002; 73:775-782.
 136. Parasrampur DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: A preliminary evaluation 2002; 42:304-11.
 137. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. *American Journal of Transplantation* 2003; 3:50-52.
 138. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. *American Journal of Transplantation* 2003; 3:306-311.
 139. Posselt AM, Vincenti FG, Bedolli M, Lantz M, Roberts JP, Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. *Transplantation* 2003; 76:190-195.
 140. Pescovitz MD, Bumgardner GL, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal

- transplantation. *Clinical Transplantation* 2003; 17:511-517.
141. Vincenti F and Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. *Transplant Proceedings* 2003; 35 (3 Suppl):S183-186S.
 142. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Sarmiento ALM, Vincenti F. Prevalence and management of anemia in renal transplant recipients: a European survey. *American Journal of Transplantation* 2003; 3:835-845.
 143. Vincenti F, Brennan TV, Fuller TF, Feng S. Optimizing the use of cyclosporine (neoral) for recipients of living donor kidneys. *Transplant Proc.* 2004; 36(Suppl 2) S50-3.
 144. Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Johnson J, Randhawa PS, Drachenberg CB, Papadimitriou JC, Weir MR, Wali RK. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. *Transplantation* 2004; 77:131-133.
 145. Lipshutz GS, Flechner S, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. *American Journal of Transplantation* 2004; 4(12):2132-4.
 146. Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlewait JR, Vincenti F, Cohen DJ. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. *Clin Transplant*; 2005 19:130-6.
 147. Vincenti F, Rostaing L. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation. *Contemporary Clinical Trials* 2005; 26:17-24.
 148. Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M, Neylan J. A Multicenter Pilot Study of Early (4-Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus. *Amer J Transplant* 2005; 5:157-166.

149. Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann E-H, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B. Prospective multicenter randomized trial to compare incidence of new onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. *Transplantation Proceedings* 2005; 37:1001-4.
150. Aziz S, Callen PW, Vincenti F, Hirose R. Rapidly Developing Nephrocalcinosis in a Patient with End-Stage Liver Disease Who Received a Domino Liver Transplant From a Patient with Known Congenital Oxalosis. Case Report. *J Ultrasound Med* 2005; 24:1449-1452.
151. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Haggerty D, Levy E, Zhou W, Natarajan K, Bernard Charpentier B, on behalf of the belatacept study group. Costimulation blockade with belatacept in renal transplantation. *N Engl J Med* 2005; 353:770-781.
152. Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu Y-M, Katz SM, Akalin E, Esterl R, Gugliuzza K, Shihab F, Jordan S, Jonsson J, Molmenti E, Barbeito R. A multicenter, prospective study of C2-monitored Neoral® in a U.S. population of de novo renal transplant recipients. *Transplantation* 2005, 80:910-916.
153. Vincenti F. Current use and future trends in induction therapy. *Saudi J Kidney Dis Transplant* 2005; 16::506-13.
154. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, Vincenti F. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. *Transplantation* 2006; 82:1004-1012.
155. Brennan TV, Fuller TF, Vincenti F, Chan S, Chang CK, Bostrom A, Zlatunich JK, Tomlanovich SJ, Feng S. Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care. *Am J Transplant*. 2006; 6:2429-35.
156. Vincenti F. Antibodies come back to the forefront in transplantation. *Clinical Journal American Society of Nephrology* 2006 1:300.
157. Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M; on behalf of the CAESAR study group. Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The

- CAESAR Study. *Am J Transplant.* 2007;7:560-70.
158. Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, Caridi G, Pavone B, Del Boccio P, Galliano M, Urbani A, Scolari F, Vincenti F, Ghiggeri GM. Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. *J Am Soc Nephrol.* 2007;18:799-810.
 159. Vincenti F, Mendez R, Pescovitz M, Rajaopalan P, Butt K, Laskow D, Slakey D, Lorber M, Garg J, Garovoy M. A phase I/II randomized open label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. *American Journal of Transplantation* 2007; 7:1770-7.
 160. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N; on behalf of the DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. *American Journal of Transplantation* 2007; 7:1506-14.
 161. Pescovitz MD, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, McKay D, Leung M, Calleja E, Bouw MR. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. *British Journal Clinical Pharmacology* 2007; 64:758-71.
 162. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephritic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. *American Journal Transplantation* 2008; 8:222-7.
 163. Vincenti F, Schena FP, Parakevas S, Hauser IA, Walker RG, Grinyo J: FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. *American Journal of Transplantation* 2008; 8:307-16.
 164. Vincenti F. Costimulation blockade in autoimmunity and transplantation. *Journal Allergy Clinical Immunology* 2008; 121:299-306.
 165. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L. Association of four DNA polymorphisms with acute rejection

- after kidney transplantation. *Transplant International* 2008; in press.
166. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. *American Journal of Transplantation* 2008; 8:1-11.
167. Vincenti F, Kirk A. What's next in the pipeline. *American Journal of Transplantation*. In press 2008.

REVIEWS AND EDITORIALS

1. Vincenti F, Amend WJC, Feduska NJ, Salvatierra O: Blood transfusions in kidney transplantation (editorial). *Arch Int Med* 142:680-681, 1982.
2. Vincenti F. Targeting the interleukin-2 receptor in clinical renal transplantation. *Graft* 1999;2:56-61.
3. Vincenti F. Daclizumab: A humanized anti-IL-2R α monoclonal antibody. *Transplantation & Immunology Letter* 1999; 15:4-6.
4. Vincenti F. Daclizumab: Novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. *Transplantation Proceedings* 1999; 31:2206-2207.
5. Vincenti F. Sparing of calcineurin antagonists: The use of interleukin-2 monoclonal antibodies in conjunction with mycophenolate mofetil. *Transplantation & Immunology Letter*, 2000; XVI: 4-6.
6. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. *American Journal of Transplantation* 2002; 2:898-903.
7. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. *J Amer Soc Neph* 2003; 14:1940-1948.
8. Vincenti F. New monoclonal antibodies in renal transplantation. *Minerva Urol Nefrol.* 2003; 55:57-66.
9. Ghiggeri GM, Carraro M, Vincenti F: Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. *Nephrology, Dialysis & Transplantation* 2004; 19:1036-1040.

10. Vincenti F. A decade of progress in kidney transplantation. *Transplantation* 2004; 77:S52-S61.
11. Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. *Transpl Int* 2004; 17:395-401.
12. Vincenti F. Chronic Induction. What's New in the Pipeline. In *Kidney Transplantation: Strategies to Prevent Organ Rejection*. Ronco C, Chiaramonte S, Remuzzi G (Eds) 146:22-29, Karger, Switzerland, 2005.
13. Vincenti F. A drug of the past, a lesson for the future. *Pediatric Transplantation* 2005; 9:267-268.
14. Vincenti F. Recurrent Focal Segmental Glomerulosclerosis in the Renal Allograft: Current Concepts of Pathogenesis, Diagnosis, and Management. *NephSap* 2005; 4:1-4.
15. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa J-V, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. *Clinical Transplantation* 2005;19:291-8. Review.
16. Vincenti F and Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. *Amer J Transpl* 2005; 5:1179-1185.
17. Vincenti F. Protein therapeutics and anti-proliferatives: a new paradigm in immunosuppression. *Transplantation Reviews* 2005; 19:179-185. Review.
18. Vincenti F. Protein therapies and antiproliferatives: a new paradigm in immunosuppression. *Transplantation Reviews* 2005, 19:179-185.
19. Vincenti F and Batty Jr. DS: The use of biologics in transplantation: a new era. *Current Opinion in Organ Transplantation* 2006; 11:19-23.
20. Hirose R and Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. *Seminars in Liver Disease* 2006; 26:201-10. Review.

22. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. *Transplantation*. 2005 Oct 15;80 (2 Suppl):S221-34. Review.
23. Vincenti F, de Andres A, Becker T, Choukroun G, Cole E, Gonzalez Posada JM, Kumar MA, Moore R, Nadalin S, Nashan B, Rostaing L, Saito K, Yoshimura N. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. *Transplant International* 2006;19:446-57. Review.
24. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, Vincenti F. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of literature. *Transplantation* 2006; 82:1004-12. Review.
24. Vincenti F and Luggen M: T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. *Annu Rev Med* 2007;48:23.
21. Tomlanovich S and Vincenti F. Sirolimus: Defining nephrotoxicity in the renal transplant recipient. *Clinical Journal American Society of Nephrology* 2007; 2: 198–199. Review.
22. Vincenti F. Costimulation blockade—what will the future bring? *Nephrol Dial Transplant* 2007; 22:1293-6. Review.
23. Yabu JM, Vincenti F. Novel immunosuppression: small molecules and biologics. *Seminars in Nephrology* 2007; 27:479-86. Review.
24. Vincenti F, Klintmalm G, Halloran PF. Open letter to the FDA: new drug trials must be relevant. *American Journal of Transplantation* 2008; 8:733-4.

CHAPTERS AND BOOKS

1. Amend WJC, Vincenti F: "Chronic renal failure and dialysis". Chapter 34 in *General Urology* Smith, (Ed) pp 413-415, Lange Medical Publications, Greenbrae, CA, 1978.
2. Vincenti F: "Renal Disease", Chapter 2, pp. 45-49; and "Acute Renal Failure", Chapter 3, pp. 73-76, Schrock, (Ed) Jones Medical Publications, Greenbrae, CA, 1978.
3. Salvatierra O, Vincenti F, Amend WJC, Feduska N: "Improved transplant survival in diabetic recipients with donor-specific blood transfusions" in

- Diabetic Renal-Retinal Syndrome*, Friedman FA, L'Esperance FA, (Eds) Grune and Stratton, Inc., 1983.
4. Vincenti F, Parfrey PS, Briggs W: "Skeletal, gastrointestinal, hepatic and hematologic disorders following kidney transplantation". In *Renal Transplantation* Garovoy MR and Guttman RD (Eds), Churchill Livingstone, 1986.
 5. Amend WJC, Vincenti F: Oliguria; Acute renal failure and Chronic renal failure and dialysis. In *General Urology*, 12th Edition, Tanaglio E (Ed), Appleton & Lange, Norwalk, pp. 526-530, 530-532, 1988.
 6. Amend WJC, Vincenti F, Tomlanovich SJ: Management of Early Allograft Dysfunction. Chapter in *Handbook of Kidney Transplantation*. Danovich, Gabriel M. (Ed.), Little Brown and Company, Boston, MA 1992.
 7. Amend WJC, Vincenti F, Tomlanovich SJ: Management of Early Allograft Dysfunction. Chapter in *Handbook of Kidney Transplantation*. Danovich, Gabriel M. (Ed.), 2nd Edition, Little Brown and Company, Boston, MA, 1996.
 8. Amend WJC, Vincenti F. Renal Transplantation. Chapter in *Hospital Medicine*. Wachter RM, Goldman L, Hollander, H. (Eds.), 1st Edition, Williams & Wilkins, 1999.
 9. Vincenti F. Induction Therapy in Renal Transplantation. Chapter in *AST Primer on Transplantation*, D. Norman and P. Halloran (Eds), 2nd Edition, 2000.
 10. Amend, WC and Vincenti, F: Chapter 34: Diagnosis of Medical Renal Disease. Chapter 35: Oliguria; Acute Renal Failure. Chapter 36: Chronic Renal Failure & Dialysis. In *Smith's General Urology* Tanagho EA, McAninch JW (Eds). Lange Medical Books/McGraw-Hill, 2000, Pg. 593-613.
 11. Ryutaro Hirose and Flavio Vincenti. Chapter 28: Review of Transplantation—1999 in *Clinical Transplants 1999*, Cecka and Terasaki, Eds., UCLA Immunogenetics Center, Los Angeles, CA, pg. 295.
 12. Vincenti F. Chapter 34: Induction Therapy in Kidney Transplantation. In *Chronic Kidney Disease, Dialysis, & Transplantation: Companion to Brenner & Rector's The Kidney*. Pereira BJG, Sayegh MH, Blake P (Eds), Elsevier Saunders, Philadelphia, PA, 2005, pp. 647-652.

13. Krensky AM, Vincenti F, Bennett W. Chapter 52: Immunomodulators: Immunosuppressants, tolerogens and immunostimulants in *The Pharmacological Basis of Therapeutics*, 11th Edition, Brunton L, Lazo JS, Parker KL (Eds) McGaw-Hill Medical Publishing, 2005, pp. 1405-1431.
14. Flavio Vincenti and Ryutaro Hirose. Chapter 11: Novel Immunosuppressants. In *Pediatric Transplantation*, 2nd edition. Richard Fine, Steven Webber, William Harmon, Deirdre Kelly and Kim Olthoff (Eds.) Blackwell Publishing, Oxford UK, 2006, pp. 89-94.